Publications, Pharmaceutical

Nasal Drug Development, Trends and Challenges with Nasal Formulations

The confluence of COVID-19, growing recognition of the potential for nose-to-brain drug delivery and the recent success of rapid rescue remedies makes it an exciting time to be working in nasal drug delivery.

This Q&A considers the critical factors that influence nasal drug product development and current trends in formulation practice and science.

The need for a better understanding of precisely where to target nasal drug delivery, and how, is highlighted, along with requirements for better models of mucociliary clearance to tackle the challenge of improving retention. Going forward it is anticipated that nasal drug delivery will be used more, and for a wider range of drugs, notably vaccines and other biologics including mRNA and antibodies.

Download the Nasal Drug Delivery Q&A
Author(s): Dr Irene Rossi
25 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out MORE ABOUT NASAL DRUG DELIVERY EXPERTISE

This Might Also Be of Interest

2 May 2023

Using Intranasal Delivery for Drug Repositioning: A Compelling Proposition for Lifecy...

Publications, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights

Read More
24 Apr 2023

The Potential and Challenge of Nasal Vaccination

Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
20 Apr 2023

Exploring Systemic Nasal Delivery: Systems & Formulations

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
27 Mar 2023

Delivery of Biologics to the Nasal Cavity: The Future of Nasal Drug Delivery

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 4 5 6 7 8 25

Request Access

Close

Requesting access to Nasal Drug Development, Trends and Challenges with Nasal Formulations.

  • This field is for validation purposes and should be left unchanged.
Back To Top